A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult ...

Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy ...

Five-year data from clinical trial for adults with relapsed or refractory large B-cell lymphoma confirms lasting remissions ...

STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

Although the readout was only from four multiple myeloma patients, attendees at the meeting wondered at how far the CAR T-cell therapy field has come.

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...

AMCP Nexus 2025 explored innovative health care policies, oncology advancements, and the impact of new regulations on patient ...

Here's a look at scientific discoveries and breakthroughs that made headlines in 2025, spanning space, biology, ecology, and ...

Factors associated with higher progression rates included double-hit/triple-hit lymphoma, high IPI status, and primary refractory disease. A recent study reveals critical insights on disease ...

A phase 1/2 clinical trial examining the CRISPR-engineered allogeneic chimeric antigen receptor (CAR)-T candidate AVC-203 (QUADvance) has been approved by the FDA and the European Medicines Agency ...

Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute ...